Kymera Therapeutics, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Kymera amended its Non-Employee Director Compensation Policy on June 24, 2026. The policy specifies annual cash retainers ($50k base board + committee fees up to $35k) and equity awards (initial $800k one-time grant vesting over 4 years, $400k annual grants). Maximum annual director compensation capped at $750k ($1M in initial year). No material changes to compensation amounts or structure are documented in this filing excerpt.
Why this rating
Routine governance housekeeping; director compensation is immaterial to $2.3B market cap and no substantive changes disclosed.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.